{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:08Z","timestamp":1788869288782,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574838"],"award-info":[{"award-number":["82574838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82405517"],"award-info":[{"award-number":["82405517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:46:03Z","timestamp":1784216763000},"page":"95-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non\u2013Small-Cell Lung Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-811X","authenticated-orcid":false,"given":"Yuhao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaihang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.cllc.2026.07.005_bib0002","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.07.005_bib0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2026.07.005_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","volume":"35","author":"Lu","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.005_bib0007","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijrobp.2024.10.022","article-title":"Phase 2 trial of consolidative stereotactic body radiation therapy in patients with metastatic oncogene-driven non-small cell lung carcinoma treated with tyrosine kinase inhibitors","volume":"121","author":"Keane","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.07.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.005_bib0009","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13014-021-01765-x","article-title":"Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy","volume":"16","author":"Jia","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2026.07.005_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2026.07.005_bib0012","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.005_bib0013","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cllc.2026.07.005_bib0014","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cllc.2026.07.005_bib0015","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.005_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2010.12.007","article-title":"Upfront gefitinib\/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience","volume":"73","author":"Chang","year":"2011","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.005_bib0017","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.ijrobp.2010.12.035","article-title":"Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer","volume":"81","author":"Wang","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.cllc.2026.07.005_bib0018","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/annonc\/mds012","article-title":"Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)","volume":"23","author":"Niho","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.005_bib0019","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/COC.0b013e31826e071b","article-title":"Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer","volume":"37","author":"Wang","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.07.005_bib0020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2147\/OTT.S62707","article-title":"Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy","volume":"7","author":"Zhuang","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"8","key":"10.1016\/j.cllc.2026.07.005_bib0021","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1634\/theoncologist.2019-0285","article-title":"Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations","volume":"24","author":"Zheng","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13014-020-01596-2","article-title":"Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial","volume":"15","author":"Fu","year":"2020","journal-title":"Radiat Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.005_bib0023","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.jtho.2021.05.019","article-title":"Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; West Japan Oncology Group 6911L","volume":"16","author":"Akamatsu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.005_bib0024","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.21037\/apm-20-1116","article-title":"Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone?","volume":"10","author":"Tang","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-021-08228-2","article-title":"Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell\u2002lung\u2002cancer: a propensity-matched retrospective study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.005_bib0026","first-page":"409","article-title":"Symptomatic radiation pneumonitis in NSCLC patients receiving EGFR-TKIs and concurrent once-daily thoracic radiotherapy: predicting the value of clinical and dose-volume histogram parameters","volume":"25","author":"Yang","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.cllc.2026.07.005_bib0027","article-title":"First-line tyrosine kinase inhibitors combined with local consolidative radiation therapy for elderly patients with oligometastatic non-small cell lung cancer harboring EGFR activating mutations","volume":"12","author":"Hu","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2026.07.005_bib0028","article-title":"Efficacy and failure patterns of early SBRT to the primary tumor in advanced EGFR-mutation-positive lung cancer with EFGR-TKI treatment: a prospective, single arm, phase II study","volume":"12","author":"Shi","year":"2022","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.005_bib0029","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12885-024-11946-y","article-title":"Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients","volume":"24","author":"Yin","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2026.07.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102853","article-title":"Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial","volume":"76","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cllc.2026.07.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241290133","article-title":"Early stereotactic body radiation therapy improves progression-free survival of first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated lung cancer: an observational cohort study","volume":"16","author":"Xu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0033","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13014-025-02649-0","article-title":"Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy","volume":"20","author":"Zhao","year":"2025","journal-title":"Radiat Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.005_bib0034","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.21037\/jtd-2025-635","article-title":"EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer","volume":"17","author":"Yuan","year":"2025","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.005_bib0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ijrobp.2015.08.012","article-title":"Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China","volume":"93","author":"Su","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.005_bib0036","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ijrobp.2024.06.018","article-title":"Phase 2 trial assessing toxicity of personalized response-based radiation treatment in patients with locally advanced non-small cell lung cancer","volume":"120","author":"Edwards","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.005_bib0037","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ijrobp.2009.09.030","article-title":"Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel","volume":"78","author":"Barriger","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.005_bib0038","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ijrobp.2011.04.016","article-title":"Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients","volume":"82","author":"Jeremi\u0107","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.005_bib0039","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.005_bib0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201002-0188OC","article-title":"EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium","volume":"183","author":"Harada","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"33","key":"10.1016\/j.cllc.2026.07.005_bib0041","doi-asserted-by":"crossref","first-page":"11772","DOI":"10.1073\/pnas.0801463105","article-title":"Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis","volume":"105","author":"Yamaoka","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1016\/j.cllc.2026.07.005_bib0042","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.3390\/ijms20164021","article-title":"Blockade of EGFR activation promotes TNF-induced lung epithelial cell apoptosis and pulmonary injury","volume":"20","author":"Yamaoka","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cllc.2026.07.005_bib0043","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/cac2.12594","article-title":"Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)","volume":"44","author":"Lu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.005_bib0044","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.005_bib0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.07.005_bib0046","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: a phase I study","volume":"12","author":"Higgins","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:38Z","timestamp":1788866318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000987"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non\u2013Small-Cell Lung Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}